empty
 
 
ar
بحث
الدعم
فتح الحساب الفوري
منصة التداول
إيداع/ سحب
بحث
للمبتدئين للمتداولين للشركاء خذ استراحة About InstaSpot
ar
For Traders
Charts
#DVAX

#DVAX (Dynavax Technologies Corporation). سعر الصرف والرسوم البيانية عبر الإنترنت.

#DHR Return to the list of instruments #DXCM

Currency converter

Dynavax Technologies Corporation
10.89 USD
09 Dec 2025 22:59
تغير السعر (% chg)
$-0.02
(-0.18%)
الاغلاق السابق
الاغلاق السابق

سعر الاغلاق فى اليوم السابق.
$10.96
الفتح
الفتح

سعر الافتتاح.
$10.93
قمة اليوم
قمة اليوم

أعلى سعر وصل اليه الزوج خلال آخر يوم تداول.
$11.12
قاع اليوم
قاع اليوم

أقل سعر وصل اليه الزوج خلال آخر يوم تداول
$10.85
قمة 52-أسبوع
قمة 52-أسبوع

أعلى سعر وصل إليه الزوج خلال آخر 52 أسبوع
$11.28
قاع 52-أسبوع
قاع 52-أسبوع

أقل سعر وصل إليه الزوج خلال آخر 52 أسبوع
$10.62
Download archive
Buy
10.89
Sell
10.89
Open the chart in full screen view
Buy
10.89
Sell
10.89
Download archive
Open the chart in full screen view

Dynavax Technologies Corporation. About company

Dynavax Technologies Corporation is a biopharmaceutical company whose core business is the development and production of vaccines.

The company’s main product is a hepatitis B drug. The company also produces vaccines against coronavirus, influenza, plague, and other infectious diseases.

In addition, the company is mainly focused on the production of adjuvants. These substances help vaccines to be better absorbed by the body.

Currently, Dynavax has a market capitalization of $1.37 billion. Last year, the company posted revenues of $438.24 million and a net income of $76.71 million.

Dynavax Technologies Corporation’s shares and what affects their price

Dynavax shares have been trading on the NASDAQ exchange under the DVAX ticker since 2004. The initial price per share stood at $7.50.

Currently, the company’s shares are trading between $10 and $12. During the year, the share price was hovering between $7 and $22. At the same time, the company does not pay dividends to its shareholders.

What to pay attention to when trading the company’s shares:

  • Long-term growth prospects are driven by a large number of innovative developments;
  • The target price for the stock is several times higher than the current one, ranging between $45.5 and $48, according to forecasts;
  • Adjuvant technology is an advantage for the company since these additional substances significantly enhance the effect of the vaccines.

لا تستطيع التحدث الآن؟
اطرح سؤالك في الدردشة.